Education
About Us
Working with TipRanks
Follow Us
Seastar Medical Holding Corporation (ICU)
:ICU
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.43Last Year’s EPS
-1.03Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 5.69%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The call highlighted significant revenue growth and progress in clinical trials and regulatory approvals, indicating strong future potential. However, challenges in trial enrollment and regulatory processes were noted as hurdles.Company Guidance
During the SeaStar Medical first quarter 2025 financial results conference call, several key metrics and updates were discussed. The company experienced a fourfold increase in revenue, reaching $293,000 compared to $68,000 in the previous quarter, driven by increased adoption of QUELIMMUNE therapy. QUELIMMUNE has been adopted by six pediatric hospitals, with more in the IRB process, targeting a $100 million annual market based on 4,000 pediatric AKI patients. SeaStar Medical also achieved 50% enrollment in their NEUTRALIZE-AKI trial, which targets the adult AKI market, estimated at 200,000 patients and a $4.5 billion market potential. The company has secured two new FDA breakthrough device designations, expanding their pipeline. Financially, SeaStar reported a net loss of $3.7 million for the quarter, a significant reduction from $12.7 million a year earlier, and ended the quarter with $5.3 million in cash. The focus remains on expanding QUELIMMUNE adoption, completing the NEUTRALIZE-AKI trial, and preparing for a PMA filing in 2026.Revenue Growth
Achieved a fourfold increase in first quarter revenue compared to the fourth quarter of 2024. This was driven by increased adoption of QUELIMMUNE therapy.
FDA Breakthrough Device Designations
Granted two new breakthrough device designations by the FDA for addressing hyperinflammation in adult and pediatric cardiac surgery, expanding the pipeline.
Enrollment Progress in NEUTRALIZE-AKI Trial
Reached 50% enrollment in the NEUTRALIZE-AKI trial for adult patients with AKI and CRRT, triggering a prespecified interim analysis.
Expansion of Customer Base
Added a nationally recognized Children's Hospital as a new QUELIMMUNE customer and are in talks with several others.
Commercial Strategy and Market Opportunity
Outlined a strategy to focus on top 50 pediatric sites in the U.S. and a $4.5 billion total annual market opportunity in the adult AKI market.
Cost Management
Managed resources effectively, resulting in lower sequential operating expenses and a strengthened balance sheet with new capital.
ICU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ICU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.23 | $1.24 | +0.81% |
Mar 27, 2025 | $2.20 | $1.70 | -22.73% |
Nov 13, 2024 | $2.52 | $1.96 | -22.22% |
Aug 13, 2024 | $6.07 | $5.01 | -17.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Seastar Medical Holding Corporation (ICU) report earnings?
Seastar Medical Holding Corporation (ICU) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Seastar Medical Holding Corporation (ICU) earnings time?
Seastar Medical Holding Corporation (ICU) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICU EPS forecast?
ICU EPS forecast for the fiscal quarter 2025 (Q2) is -0.43.